{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-097804","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.977489+00:00","generated_at":"2026-06-11T00:37:44.543801+00:00","sec_items":["1.01","3.02","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NRx Pharmaceuticals raises $1.2M via private placement of preferred shares and warrants at $0.40","bullets":["Issued 3M shares of Series A Preferred Stock and 3M warrants, each at $0.40, raising ~$1.2M from existing investors.","Preferred shares convert to common stock after 6 months or earlier if stock price reaches $1.20 per share.","Warrants exercisable at $0.40 per share for 5 years, also early conversion if $1.20 trigger met.","Proceeds to fund development of NRX-101 for Suicidal Bipolar Depression and Chronic Pain, plus general corporate purposes.","Certificate of Designation filed with Delaware authorizing up to 12M shares of Series A Preferred."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-097804","json":"https://secwatch.observer/filing/0001104659-23-097804.json","markdown":"https://secwatch.observer/filing/0001104659-23-097804.md","text":"https://secwatch.observer/filing/0001104659-23-097804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/0001104659-23-097804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/tm2317653d12_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:37:44.543801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85430d2799e515d0b7c17fcccd7ccecbdb6e7ae2","claim":"NRX Pharmaceuticals, Inc.: Filed Certificate of Designation for Series A Convertible Preferred Stock, establishing preferences, rights, and limitations (effective 2023-08-30).","evidence_excerpt":"On August 30, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Delaware Secretary of State (the \"Certificate of Designation\") authorizing up to 12,000,000 shares of Series A Convertible Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/0001104659-23-097804-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-30"}],"fact_type":"governance_change"},{"claim_id":"ac0e1880009eac47e6c36eaed506dbd383aea9eb","claim":"NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers signatory thereto (the \"Investors\") valued at approximately $1.2 million (effective 2023-08-28).","evidence_excerpt":"On August 28, 2023, the Company entered into a securities purchase agreement (the \"Securities Purchase Agreement\") with the purchasers signatory thereto (the \"Investors\"), pursuant to which the Company issued 3,000,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share (the \" Series A Preferred Stock \"), and one (1) investor warrant (each an \"Investor Warrant\") for every share of Series A Convertible Preferred Stock issued.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/0001104659-23-097804-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers signatory thereto (the \"Investors\")"},{"label":"Value","value":"approximately $1.2 million"},{"label":"Effective","value":"2023-08-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}